news
Newer blood thinners slow cognitive decline in Alzheimer's patients
New research shows Non-vitamin K antagonist Oral Anticoagulants (NOACs) like rivaroxaban and apixaban may slow cognitive decline in Alzheimer's patients with atrial fibrillation. Compared to warfarin or no treatment, patients on NOACs experienced a more gradual decrease in cognitive function. This suggests an unexpected benefit beyond stroke prevention, accumulating over time.
New research shows Non-vitamin K antagonist Oral Anticoagulants (NOACs) like rivaroxaban and apixaban may slow cognitive decline in Alzheimer's patients with atrial fibrillation. Compared to warfarin or no treatment, patients on NOACs experienced a more gradual decrease in cognitive function. This suggests an unexpected benefit beyond stroke prevention, accumulating over time.
The architecture take
I've been watching this space for a while; the connection between micro-clots, inflammation, and cognitive decline just keeps getting clearer. This study, while modest year-to-year, is another strong signal. It isn't just about preventing a big stroke anymore; these NOACs seem to guard against the tiny vascular insults that chip away at brain function. It makes sense: a cleaner blood flow means better oxygen and nutrient delivery, less oxidative stress, and lower inflammation in the brain. For someone managing Alzheimer's and AFib, it's a double win. I'm curious if we'll see this mechanism explored in other neurodegenerative conditions, or if the protective effect could extend to people without AFib, maybe even as a longevity play. It points to a future where brain health interventions go beyond just neurons to the circulatory system feeding them.